Filing Details
- Accession Number:
- 0001209191-10-054143
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-11-10 12:34:46
- Reporting Period:
- 2010-11-08
- Filing Date:
- 2010-11-10
- Accepted Time:
- 2010-11-10 12:34:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1365619 | Laura Brege | C/O Onyx Pharmaceuticals, Inc. 2100 Powell St. Emeryville CA 94608 | Evp & Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-11-08 | 25,000 | $15.44 | 43,514 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2010-11-08 | 25,000 | $30.00 | 18,514 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2010-11-08 | 25,000 | $0.00 | 25,000 | $15.44 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 75,000 | 2016-06-12 | No | 4 | M | Direct |
Footnotes
- Includes 388 shares purchased through the issuer's ESPP.
- Shares sold pursuant to a 10b5-1 plan.
- Twenty-Five percent of the shares subject to the option become exercisable 1 year from the date of grant and the remainder become exercisable at a rate of 1/48th per month thereafter.
Billionaire Hedge Funds
